Double-targeted Nanostructured Lipid Carriers with Anti-VEGFR-2 Antibody for Tumor Specific Therapy
Purpose: This study aimed to develop and evaluate a one-double targeting drug delivery system. Methods: Flk-l(A-3), a mouse monoclonal anti-VEGFR-2 antibody, modified docetaxel (DTX)-loaded targeted nanostructured lipid carriers (tNLC) has been constructed. The cellular cytotoxicity, uptake, in vivo therapeutic effect and biodistribution were investigated. Results: The tNLC showed better tolerant and antitumor efficacy in murine model bearing B16 compared with Duopafei?or nNLC. The results of cellular uptake and biodistribution studies indicated the better antitumor efficacy of tNLC was attributed to both the increased accumulation of drug in tumor and tumor vasculature. Conclusion: The double-targeted NLC with anti-VEGFR-2 antibody could efficiently deliver DTX to the targeted tumor vasculature and tumor site.
Docetaxel double target nanostructured lipid carriers anti-VEGFR-2 antibody tumor therapy
Chunxi Liu Donghua Liu Na Zhang
Department of Pharmaceutics, School of Pharmaceutical Science, Shandong University, 44 West Culture Road,Jinan 250012, China
国际会议
The Second Asian Symposium on Pharmaceutical Sciences and Technology(第二届亚洲药物制剂科学研讨会)
西安
英文
61-62
2011-09-19（万方平台首次上网日期，不代表论文的发表时间）